L-tyrosine third party tested
Selected indexed studies
- Cost-effectiveness of biomarker-based and universal strategies for the treatment of advanced-stage endometrial cancer. (Gynecol Oncol, 2025) [PMID:41187375]
- Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients. (J Natl Cancer Inst, 2025) [PMID:40796347]
- Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. (Pharmacoeconomics, 2015) [PMID:25404424]
_Worker-drafted node — pending editorial review._
Connections
L-tyrosine third party tested helps
Sources
- Cost-effectiveness of biomarker-based and universal strategies for the treatment of advanced-stage endometrial cancer. (2025) pubmed
- Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients. (2025) pubmed
- Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. (2015) pubmed
- HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. (2022) pubmed
- HER2 testing results, practices, and preferences among pathologists and oncologists in the US community setting: a mixed-methods study. (2025) pubmed
- First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. (2013) pubmed
- Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany. (2020) pubmed
- Quantitative urine testing. A new tool for diagnosing and treating cocaine use. (1989) pubmed